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available on the Mexican Formulary Catalog (naproxen/esomeprazole, NSAIDs 
group and celecoxib). Incremental cost-effectiveness ratio (ICER) was performed 
with two measures: Life Years without AE (LY) and Quality Adjusted Life Years 
(QALYs). The analysis was done from public perspective, only considered direct 
costs, and is reported in US dollars. RESULTS: Treatment with 
naproxen/esomeprazole versus NSAIDs represents an ICER of $318.85 for one 
year without AE; celecoxib had an ICER of $1,226.59, less effective than 
naproxen/esomeprazole. The ICER per QALY gain was $1,363.26 for 
naproxen/esomeprazole and $4,562.90 for celecoxib. Sensitivity analysis 
confirms the consistency of the results. CONCLUSIONS: Naproxen/esomeprazole 
FDC dominated celecoxib and NSAIDs. The use of naproxen/esomeprazole in the 
treatment of patients with OA at risk of developing GI AE is cost-effective and 
could be considered as the first option in an institutional setting.  
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THE ECONOMIC VALUE OF AN INNOVATIVE KNEE IMPLANT SYSTEM FOR 
TOTAL KNEE ARTHROPLASTY  
Ronquest N1, Mladsi DM1, Hopley C2, Edgell ET3 
1RTI Health Solutions, Research Triangle Park, NC, USA, 2DePuy UK, Leeds, UK, 3DePuy 
Orthopaedics, Inc., Warsaw, IN, USA  
OBJECTIVES: New Innovative Knee Implants (IKIs) have the potential to reduce 
patients' awareness of the artificial knee, increase their confidence in 
performing daily activities, and reduce problems leading to revisions compared 
with Contemporary Knee Implants (CKI). This study aimed to illustrate the 
expected economic value of a new IKI among osteoarthritis (OA) patients 
requiring total knee arthroplasty (TKA). METHODS: A Markov model was 
developed to explore the cost-effectiveness of the IKI compared with CKIs among 
OA patients undergoing TKA from a United States payer perspective. The model 
design distinguished between the IKI and CKIs in terms of functional status and 
implant survivorship. CKI survivorship was estimated using patient-level 
survivorship data with SIGMA fixed bearing knees from the United Kingdom 
National Joint Registry. To estimate IKI survivorship, the approach used by Suter 
et al. (2011) was adopted. Adjustments were made to the risk of revision for 
causes addressed in the design of the IKI, specifically, wear, loosening, pain, 
instability, patella maltracking, and stiffness. Costs and utilities associated with 
various health states were literature based. RESULTS: The model predicts that 
the IKI will reduce revisions by nearly 20% and that this improvement in 
survivorship will translate to economic savings. Additionally, independent of 
survivorship, improvements in patient functioning will result in economic value. 
The IKI is expected to be cost-neutral with improved health, when restricting the 
expected benefit to survivorship only, or to be a therapy that both improves 
health and reduces costs when functional improvements are also considered. 
CONCLUSIONS: Although TKA can be a successful intervention, there is still 
potential for IKIs to provide clinical and economic value. Further investigation to 
quantify the link between improvement in IKI design features and clinical 
outcomes is necessary to improve the understanding of potential IKI clinical and 
economic benefits.  
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COST-EFFECTIVENESS OF DENOSUMAB IN THE TREATMENT OF 
POSTMENOPAUSAL OSTEOPOROSIS (PMO) WOMEN IN MEXICO AT HIGH RISK 
OF FRACTURES AND INTOLERANT TO ORAL BISPHOSPHONATES  
Arocho R1, Rivera Hurtado R2, Salinas Escudero G3 
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OBJECTIVES: The aim of the study was to evaluate the cost-effectiveness of 
denosumab (60 mg every 6 months) in the treatment of postmenopausal 
osteoporosis (PMO) women in México at high risk of fractures and intolerant to 
oral bisphosphonates. METHODS: The study was conducted from the public 
payer perspective using the comparators of raloxifene (60 mg daily) and 
teriparatide (20 mcg daily). High risk was defined as having 2 of the following 3 
risk factors: Age ≥70 years, T-score ≤-3 or previous fracture. Life years gained 
(LYG) were the effectiveness measure used in the model. The model reported the 
weighted Incremental Cost-effectiveness Ratio (ICER) for 3 possible scenarios: 1) 
Age ≥70 years and T-score ≤-3, without previous fracture; 2) Age ≥ 70 years with 
previous fracture; 3) T-score ≤-3 with previous fracture. A Markov model was 
performed using a lifetime horizon and 5 years of treatment. The Diagnoses-
Related Groups costs reported by Mexican Institute for Social Security (IMSS) for 
Mexico were used for different types of fractures. A discount rate of 5% was used 
for costs and health outcomes. The costs were reported in 2011 Mexican pesos. 
RESULTS: According to the average results for the 3 scenarios, the costs are 
$199,546 pesos for raloxifene, $202,969 pesos for denosumab and $269,304 pesos 
for teriparatide. The incremental cost per LYG with denosumab in comparison 
with raloxifene is $42,775 Mexican pesos and $-941,995 Mexican pesos versus 
teriparatide. CONCLUSIONS: Denosumab is a cost-effective alternative versus 
raloxifene because the ICER is 22% below to 1 GDP per capita (local cost-
effectiveness threshold). Also, denosumab can be considered a cost-saving 
alternative versus teriparatide because it reduces costs and increases clinical 
benefits in the treatment of PMO women in Mexico at high risk for fracture and 
intolerant to oral BPs.  
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COST-UTILITY ANALYSIS OF TOCILIZUMAB IN THE TREATMENT OF ACTIVE 
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OBJECTIVES: Systemic idiopathic juvenile arthritis (sJIA) is a subtype of juvenile 
idiopathic arthritis (JIA), characterized by systemic manifestations of disease in 
addition to arthritis leading to significant patient morbidity, caregiver burden, 
and health care costs. The TENDER study demonstrated that treatment with 
tocilizumab resulted in a significant benefit over placebo. The objective of this 
study is to determine the cost-effectiveness of tocilizumab with or without 
methotrexate compared to placebo with methotrexate for the treatment of sJIA. 
METHODS: A Markov model was developed to capture time spent by patients in 
various health states, which included: no American College of Rheumatology 
(ACR) Response (uncontrolled), ACR Response 30, 50, 70, 90, and Death. Results 
were reported as incremental cost per additional quality adjusted life-years 
(QALY) gained, over a 16-year period (from age 2-18 years). Transition 
probabilities were derived from the TENDER study and published literature. The 
base case analysis focused on direct medical costs only from the perspective of 
the Canadian Ministry of Health (MoH). A second analysis was conducted from 
the societal perspective. Cost data were obtained from a variety of sources and 
reported as 2011 Canadian Dollars. A 5% discount rate was applied to both costs 
and patient outcomes. Multiple sensitivity analyses were undertaken to test the 
robustness of the model. RESULTS: From the MoH perspective, tocilizumab with 
or without methotrexate had an incremental cost-utility ratio (ICUR) of $69,787 
per additional QALY gained compared to placebo with methotrexate. The 
treatment with tocilizumab would be the dominant (less costly and more 
effective) treatment strategy from the societal perspective. Results were robust 
over a wide range of sensitivity analyses tested. CONCLUSIONS: Tocilizumab 
with or without methotrexate is a cost-effective strategy compared to placebo 
with methotrexate for patients with sJIA.  
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COMPARISON OF COST PER QALY (QUALITY-ADJUSTED LIFE YEAR) FOR  
MAJOR TYPES OF CANCERS, END-STAGE RENAL DISEASE AND RHEUMATOID 
ARTHRITIS IN TAIWAN: A POPULATION-BASED STUDY DURING  
1998-2007  
Hung MC1, Wang JD2 
1Department of Public Health, National Cheng Kung University Medical College, Tainan, Taiwan, 
2National Cheng Kung University College of Medicine, Tainan, Taiwan  
OBJECTIVES: This study determines the lifetime survival function, utility 
function and health care expenditure for 8 types of cancer, end-stage renal 
disease (ESRD) and rheumatoid arthritis (RA) stratified by gender and age in 
Taiwan, and provides data to estimate cost-per-QALY for comparison. 
METHODS: A total of 335,918 pathologically verified cancer patients registered in 
the National Cancer Registry of Taiwan during 1998-2007, and 125,277 ESRD 
patients and 39, 455 RA patients registered under “catastrophic illnesses” were 
included. All of them were followed until the end of 2010 to obtain the survival 
function, which were further extrapolated to lifetime based on a semi-
parametric method using the age- and sex-matched referents simulated from 
the life tables of the National Vital Statistics of Taiwan. The survival functions 
were adjusted using an EQ-5D utility value derived from a convenience sample of 
8,421 patients to estimate quality-adjusted life expectancies (QALE). The monthly 
health care expenditures attributable to different cancers, ESRD and RA were 
collected from the reimbursement database of the National Health Insurance 
(NHI). These values were multiplied by the corresponding survival probabilities 
to calculate the lifetime health care expenditure after adjusting consumer price 
indices for different calendar year up to 2010 and assumed a 3% discount rate 
later on. RESULTS: ESRD had the highest life-time health care expenditure and 
cost-per-QALY, followed by RA and cancers, which is 16,933 to 17,851 U.S. dollars 
(USD) of cost-per QALY, or about one GDP (gross domestic products) of Taiwan. 
Of the 8 different cancers studied, the lung cancer, esophagus cancer and liver 
cancer had the highest cost-per-QALY. There appears a trend of shorter life 
expectancy or QALY associated with higher cost-per-QALY. CONCLUSIONS: Such 
estimates of cost-effectiveness are an essential part on the consideration to 
accommodate new health technology in cancer and other chronic diseases 
control, including prevention.  
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ASSOCIATION BETWEEN RITUXIMAB ADHERENCE AND ORAL 
GLUCOCORTICOID USE IN RHEUMATOID ARTHRITIS PATIENTS WITH PRIOR 
EXPOSURE TO ANTI-TUMOR NECROSIS FACTOR-ALPHA THERAPY  
Johnston SS1, Kamath T2, Shi N3, Fowler R1, Chu BC4, Reiss W2 
1Truven Health Analytics, Washington, DC, USA, 2Genentech, South San Francisco, CA, USA, 
3Truven Health Analytics, Cambridge, MA, USA, 4Truven Health Analytics, Santa Barbara, CA, 
USA  
OBJECTIVES: Oral glucocorticoids (OGCs) have therapeutic benefits in 
rheumatoid arthritis (RA), but can produce adverse effects. This study examined 
the association between rituximab adherence and OGC use reduction in RA 
patients. METHODS: Retrospective study using a large U.S. claims database. 
Patients included for study had initiated rituximab between March 1, 2006-March 
31, 2011 (initiation date=index), had pre-index exposure to anti-tumor necrosis 
factor-alpha (anti-TNF) therapy, were aged ≥18 years, had a medical claim with a 
diagnosis code for RA (ICD-9-CM 714.0x) between January 1, 2004-March 31, 2011, 
were continuously enrolled for 12 months before and ≥270 days after index, and 
had OGC use ≤30 days before index. Patients were excluded if they had medical 
claims with diagnosis codes for non-RA indications of biologic disease modifying 
antirheumatic drugs (BDMARDs). Based on rituximab infusion services dates and 
recommended 6-month reinfusions, rituximab exposure periods were 
constructed to start upon index and end at the first occurrence of switch to a 
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different BDMARD, disenrollment from health insurance, reaching March 31, 
2011 or follow-up of 36 months. Exposure periods were subdivided into a 
quarterly (90-day) repeated-measures panel dataset. Within each quarter-panel, 
OGC use and rituximab adherence, measured using the proportion of days 
covered (PDC), were measured. Multivariable generalized estimating equation 
models examined the association between quarterly OGC use and prior quarter 
(lagged) PDC, adjusting for confounding variables. Multivariable-adjusted OGC 
use probabilities were predicted by PDC level (PDC=0 [i.e., reinfusion≥90 days 
late]; PDC=50 [reinfusion=45 days late]; PDC≥100 [reinfusion=on time/early]) 
using the G-computation method. RESULTS: Sample comprised 4,583 quarter-
panels (594 unique patients); mean age 55 years, 81% female. The multivariable-
adjusted OGC use probabilities decreased with time (p<0.001) and increasing PDC 
(p=0.006): from approximately 0.72 for all PDC levels in the first quarter-panel to 
0.64 (PDC=0), 0.55 (PDC=50), and 0.47 (PDC≥100) in the last (12th) quarter-panel. 
CONCLUSIONS: Increasing rituximab adherence was associated with statistically 
significant OGC use reduction over time.  
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OBJECTIVES: To estimate the adherence to oral bisphosphonate medication use 
and its associated factors for patients with osteoporosis in Tianjin, China. 
METHODS: Data were obtained from the Tianjin Urban Employee Basic Medical 
Insurance (UEBMI) database (2008-2010) with 30% random selection. Patients 
with ≥ 1 osteoporosis diagnosis, aged 40 years and older, and who had ≥ 1 
pharmacy claim for oral bisphosphonate, including alendronate and etidronate, 
were selected. 12-month continuous enrollment before and after the first 
pharmacy claim for oral bisphosphonate were required. Adherence was 
measured with a medication possession ratio (MPR) and accounted for 6-month 
and 12-month. Multivariate logistic regression (MLR) analysis was conducted to 
assess the odds ratios (ORs) with 95% confidence intervals (CI) of potential 
confounding factors. RESULTS: A total of 918 patients with osteoporosis were 
identified with 64.9% female and a mean age of 64.7 (±10.4) years. The mean MPR 
was 0.24 (±0.25) and 0.13 (±0.15) at 6-month and 12-month follow-up period 
respectively. 96.62% of patients with MPR <50% and 81.05% of patients with MPR 
<20% were found in the 12-month analyses compared with 87.25% and 62.42% in 
the 6-month analysis respectively. During the first 6-month period, 48.69% of 
patients had only one bisphosphonate pharmacy claim and decreased to 47.82% 
when followed to 12-month. MLR results showed that patients with prior 
fractures during the study period may have better compliance (OR=3.15 and 
CI=1.23-8.10) while patients with coronary disease may have poorer compliance 
(OR=0.18 and CI=0.69-0.48) after adjusting for patients demographic and 
comorbidity characteristics. CONCLUSIONS: The adherence of oral 
bisphosphonate therapy for osteoporosis patients in Tianjin was significantly 
poorer compared to previous research in developed countries. More attentions 
should be paid and policy guidance is needed to improve the medication 
adherence among patients with osteoporosis in China.  
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EVALUATING THE DIFFERENTIAL IMPACT OF PHYSICAL VERSUS MENTAL  
CO-MORBIDITIES ON THE HEALTH STATE UTILITIES OF PATIENTS WITH 
ARTHRITIS, ASTHMA, DIABETES AND MIGRAINE  
Rendas-Baum R, Miller K, Livote E, White MK 
Optum, Lincoln, RI, USA  
OBJECTIVES: To examine the differential impact of a physical versus a mental 
co-morbid condition on the health state utility (HSU) of patients with an existing 
physical condition. METHODS: Four base physical (B-Phys) conditions were 
examined: arthritis, asthma, diabetes and migraine. For each B-Phys, 5 physical 
co-morbidities (Co-Phys) were selected based on published clinical and 
epidemiologic studies; depression and anxiety were selected as the 2 mental co-
morbidities (Co-Mental). Mean HSUs (and 95% confidence intervals) were 
calculated for patients with only B-Phys and for patients with the B-Phys and 
either a Co-Phys or a Co-Mental. Data came from individuals (N=26,885) with one 
or two of the selected conditions who participated in the National Health and 
Wellness Study between 2007 and 2010. HSUs, calculated based on the SF-6D, 
were age- and gender-adjusted to reflect the mean age and gender composition 
of the sample. RESULTS: Patients with a Co-Phys had lower HSUs (mean 
differences ranged from -0.018 for asthma, to -0.061 for diabetes) when 
compared to patients with only B-Phys. However, these differences were 
substantially greater for subjects with a Co-Mental instead of a Co-Phys (mean 
differences ranged from -0.081 for asthma, to -0.093 for arthritis). The mean 
difference between the HSUs of patients with only the B-Phys and those of 
patients with both B-Phys and Co-Mental were between 1.4 (Diabetes) and 4.5 
(Asthma) times higher than the difference between patients with B-Phys and B-
Phys and Co-Phys. CONCLUSIONS: Economic evaluations of interventions are 
often based on published utilities among patients with a specific condition 
regardless of their other co-morbidities. Our results suggest that having a Co-
Mental has a substantially greater impact on HSUs than a Co-Phys. Studies 
aimed at evaluating interventions among patients with a particular condition 
must take into account the prevalence and type of co-morbidities among the 
population of interest.  
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RACE DIFFERENCES IN WALKING SPEED  
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OBJECTIVES: Physical function(PF) is an important determinant of health in the 
osteoarthritis (OA) population. Patient reported outcomes(PRO) are often used as 
primary endpoints for clinical research yet PROs measure attributes of PF that 
differ from performance-based measures [i.e., walking speed(WS)]. WS has been 
proposed as the “ sixth vital sign,” and a powerful predictor of health status and 
functional decline. The purpose of this study was to determine whether WS 
differs between community-dwelling African-American (AA) and White 
American (WA) adults with OA symptoms. METHODS: Participants were 1371 
individuals (27% African American) from the Osteoarthritis Initiative, a 
prospective observational cohort. Included individuals had both 1) ≥ 1 pain, 
aching, or stiffness in or around the knee on most days for at least 1 month 
during the past 12 months, and 2) the presence of osteophytes-grade 1. Linear 
regression models examined racial differences in WS adjusting for age, gender, 
education, body mass index (BMI), income, education, waist circumference, and 
comorbidities. RESULTS: WS was significantly slower for AA than WA, (mean 
speed 1.15m/s vs. 1.31m/s; p<0.001). Compared to the WA cohort, the AA cohort 
had more females (71% vs. 51%; p<0.001), were younger [mean age(SD) 60.0(8.5) 
vs. 61.9 (9.3); p<0.001], had a higher mean BMI [32.4(5.0)kg/m2 vs. 29.4(4.7) kg/m2; 
p<0.001], and lower income and education level. AAs had higher (p<0.001) 
prevalence of hypertension (18% vs. 10%), diabetes (23% vs. 7%), and rheumatoid 
arthritis (9.9% vs. 1.1%). Racial differences in WS persisted when controlling for 
age, gender, education, body mass index (BMI), income, education, waist 
circumference, and comorbidities (excluding RA). CONCLUSIONS: In this study, 
race is an independent predictor of WS. Establishing National Norms for WS by 
race and gender should be investigated before using WS as a health status 
measure and health outcome predictor.  
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QUALITY OF LIFE IN RHEUMATOID ARTHRITIS: HOW MUCH DO WE REALLY 
KNOW?  
Rolfe F, Kusel J, Brooks-Rooney C, Leonard SA 
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OBJECTIVES: Quality of life (QoL) is increasingly being included as a secondary 
endpoint in clinical trials, with reimbursement agencies requesting information 
on the wider impact of an intervention on the patient. The quality-adjusted life 
years (QALYs) used in cost-utility analyses take their weighting of life years 
gained with an intervention from the QoL scores calculated using utility 
instruments such as the EQ-5D. The question that this poses is, what precisely 
are such utility instruments measuring, and is this a good reflection of the 
improvements in health that society wishes to finance? The aim of this study 
was to use the case study of rheumatoid arthritis (RA) to demonstrate the extent 
to which clinical trials add to our understanding of the psycho-social QoL 
outcomes of an intervention, as opposed to pain and physical function. 
METHODS: All completed phase III/IV trials in RA with results listed on 
ClinicalTrials.gov were assessed for QoL outcomes and utility instrument used. 
The relative proportion of each instrument accounting for ‘psycho-social’ versus 
‘pain and physical function’, as defined by the SF-36 dimensions, was compared. 
RESULTS: Of the 76 studies analysed, 20 measured QoL (16 using SF-36, 2 using 
EQ-5D, 4 using both). The percentage of variance in each instrument attributable 
to pain and physical function versus psycho-social outcomes, as defined by SF-
36 dimensions, was applied to these results (EQ-5D: 88.8%=Pain and physical 
function, 11.2%=Psycho-social; SF-6D: 70.5%=Pain and physical function, 
29.5%=Psycho-social). It was found that only 24.5% of the QoL results available 
report on the psychosocial implications of the intervention. CONCLUSIONS: In 
conclusion, only a very small proportion of trials in this chronic condition 
measure the QoL outcomes of their interventions, and breaking down utility 
instruments into their component dimensions shows that only a small 
proportion of the total QoL outcomes reflect psycho-social implications.  
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EMPIRICAL COMPARISON OF DISCRETE CHOICE EXPERIMENT AND BEST-
WORST SCALING TO ESTIMATE STAKEHOLDERS' RISK TOLERANCE FOR HIP 
REPLACEMENT SURGERY  
van Dijk JD1, Groothuis-Oudshoorn KG1, Marshall D2, IJzerman MJ1 
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OBJECTIVES: Empirical comparison of two preference elicitation methods, 
discrete choice experiment (DCE) and profile case best-worst scaling (BWS), 
regarding the estimation of the risk tolerance for hip replacement surgery (total 
hip arthroplasty and total hip resurfacing arthroplasty). METHODS: An online 
survey was constructed, following international guidelines, and consisted of 
socio-demographic questions and two randomised sections with 12 DCE and 8 
BWS questions. The survey was sent to a general population who can be faced 
with choosing between THA and TRA (males between 45-65 years old) in the US. 
After an intensive literature search, the following attributes were selected: 
probability of a first and a second revision in seven years, pain relief, ability to 
perform moderate daily activities, and hospital stay. In addition, survey 
respondents rated the difficulty of each method and the time to complete each 
section was monitored. BWS and DCE data was analysed using conditional logit 
analysis. The maximum acceptable risk (MAR) for a revision was estimated for 
four different hypothetical hip replacement scenarios. RESULTS: The final data 
set consisted of 429 respondents. The MARs estimated for four hypothetical hip 
replacement scenarios differed between both methods, ranging from 0% to 19% 
difference for a first revision. BWS questions took significantly more time (401 s.) 
than DCE (228 s.) questions. And respondents found BWS more difficult to 
complete. CONCLUSIONS: Both methods to elicit stakeholder preferences 
produce different results. Yet, both seem to be consistent in predicting risk 
